Christian Förster1, Miriam Giovanna Colombo, Anna-Jasmin Wetzel, Peter Martus, Stefanie Joos. 1. Institute for General Practice and Interprofessional Care, University Hospital Tübingen; Institute for Clinical Epidemiology and Applied Biometrics, University Hospital Tübingen; Center for Public Health and Healthcare Research, University Hospital Tübingen.
Abstract
BACKGROUND: After recovering from coronavirus disease 2019 (COVID-19), a considerable number of patients report long-term sequelae. The epidemiologic data vary widely in the studies published to date, depending on the study design and the patient cohorts analyzed. Using a population-based approach, we report symptoms and clinical characteristics following COVID-19 (long COVID), focusing on symptoms ≥ 12 weeks (post-COVID-19). METHODS: In three German administrative districts, all adult patients with a diagnosis of COVID-19 confirmed by polymerase chain reaction (PCR) between March and September 2020 (n = 4632) were invited to complete a questionnaire. Predictors for post-COVID-19 were identified by multiple ordinal regression analysis. Study registration: DRKS00023069. RESULTS: A total of 1459 patients were included in the study, 175 (12%) of whom had been hospitalized for treatment of the acute phase of COVID-19. The prevalence of post-COVID-19 was 72.6% (n = 127) and 46.2% (n = 588) for hospitalized and non-hospitalized patients, respectively. The most frequently occurring long-term symptoms were fatigue (41.5% of all symptoms ≥ 12 weeks, n = 297), physical exhaustion (40.8%, n = 292), difficulty in concentrating (30.6%, n = 219), and loss of the senses of taste (25.9%, n = 185) and smell (25.5%, n = 182). Quality of life was significantly impaired in patients with post-COVID-19. The strongest risk factors for post-COVID-19 were female sex, overall severity of comorbidities, and severity of acute COVID-19. CONCLUSION: Patients who are not hospitalized also frequently experience continued symptoms following COVID-19. The heterogeneity of symptoms calls for a multi - disciplinary stepped-care approach, for which identification of patients at risk is crucial. A limitation of the study is the lack of a control group.
BACKGROUND: After recovering from coronavirus disease 2019 (COVID-19), a considerable number of patients report long-term sequelae. The epidemiologic data vary widely in the studies published to date, depending on the study design and the patient cohorts analyzed. Using a population-based approach, we report symptoms and clinical characteristics following COVID-19 (long COVID), focusing on symptoms ≥ 12 weeks (post-COVID-19). METHODS: In three German administrative districts, all adult patients with a diagnosis of COVID-19 confirmed by polymerase chain reaction (PCR) between March and September 2020 (n = 4632) were invited to complete a questionnaire. Predictors for post-COVID-19 were identified by multiple ordinal regression analysis. Study registration: DRKS00023069. RESULTS: A total of 1459 patients were included in the study, 175 (12%) of whom had been hospitalized for treatment of the acute phase of COVID-19. The prevalence of post-COVID-19 was 72.6% (n = 127) and 46.2% (n = 588) for hospitalized and non-hospitalized patients, respectively. The most frequently occurring long-term symptoms were fatigue (41.5% of all symptoms ≥ 12 weeks, n = 297), physical exhaustion (40.8%, n = 292), difficulty in concentrating (30.6%, n = 219), and loss of the senses of taste (25.9%, n = 185) and smell (25.5%, n = 182). Quality of life was significantly impaired in patients with post-COVID-19. The strongest risk factors for post-COVID-19 were female sex, overall severity of comorbidities, and severity of acute COVID-19. CONCLUSION: Patients who are not hospitalized also frequently experience continued symptoms following COVID-19. The heterogeneity of symptoms calls for a multi - disciplinary stepped-care approach, for which identification of patients at risk is crucial. A limitation of the study is the lack of a control group.
Authors: Christoph Pieh; Sanja Budimir; Jaime Delgadillo; Michael Barkham; Johnny R J Fontaine; Thomas Probst Journal: Psychosom Med Date: 2021-05-01 Impact factor: 4.312
Authors: Oscar Moreno-Pérez; Esperanza Merino; Jose-Manuel Leon-Ramirez; Mariano Andres; Jose Manuel Ramos; Juan Arenas-Jiménez; Santos Asensio; Rosa Sanchez; Paloma Ruiz-Torregrosa; Irene Galan; Alexander Scholz; Antonio Amo; Pilar González-delaAleja; Vicente Boix; Joan Gil Journal: J Infect Date: 2021-01-12 Impact factor: 6.072
Authors: Amy Parkin; Jennifer Davison; Rachel Tarrant; Denise Ross; Stephen Halpin; Alex Simms; Rashad Salman; Manoj Sivan Journal: J Prim Care Community Health Date: 2021 Jan-Dec
Authors: Hannah E Davis; Gina S Assaf; Lisa McCorkell; Hannah Wei; Ryan J Low; Yochai Re'em; Signe Redfield; Jared P Austin; Athena Akrami Journal: EClinicalMedicine Date: 2021-07-15
Authors: Temet M McMichael; Dustin W Currie; Shauna Clark; Sargis Pogosjans; Meagan Kay; Noah G Schwartz; James Lewis; Atar Baer; Vance Kawakami; Margaret D Lukoff; Jessica Ferro; Claire Brostrom-Smith; Thomas D Rea; Michael R Sayre; Francis X Riedo; Denny Russell; Brian Hiatt; Patricia Montgomery; Agam K Rao; Eric J Chow; Farrell Tobolowsky; Michael J Hughes; Ana C Bardossy; Lisa P Oakley; Jesica R Jacobs; Nimalie D Stone; Sujan C Reddy; John A Jernigan; Margaret A Honein; Thomas A Clark; Jeffrey S Duchin Journal: N Engl J Med Date: 2020-03-27 Impact factor: 91.245
Authors: Claudia Peters; Madeleine Dulon; Claudia Westermann; Agnessa Kozak; Albert Nienhaus Journal: Int J Environ Res Public Health Date: 2022-06-07 Impact factor: 4.614
Authors: Benjamin Giszas; Sabine Trommer; Nane Schüßler; Andrea Rodewald; Bianca Besteher; Jutta Bleidorn; Petra Dickmann; Kathrin Finke; Katrin Katzer; Katja Lehmann-Pohl; Christina Lemhöfer; Mathias W Pletz; Christian Puta; Stefanie Quickert; Martin Walter; Andreas Stallmach; Philipp Alexander Reuken Journal: Infection Date: 2022-07-22 Impact factor: 7.455
Authors: Ewan Donnachie; Alexander Hapfelmeier; Klaus Linde; Martin Tauscher; Roman Gerlach; Anna Greissel; Antonius Schneider Journal: BMJ Open Date: 2022-09-22 Impact factor: 3.006